The most fundamental change in asthma management in 30 years?
- PMID: 31754073
- DOI: 10.1183/13993003.01583-2019
The most fundamental change in asthma management in 30 years?
Conflict of interest statement
Conflict of interest: I. Amirav has nothing to disclose. Conflict of interest: M.T. Newhouse is employed by InspiRx Pharmaceuticals Inc. as the Chief Medical Officer and has patents through InspiRx Pharmaceuticals Inc. (6,470.882; 8,119,016; D 689,602; D 685,085; and D 686725; pending: US 2012/0318261 and 2012/0318265).
Comment on
-
GINA 2019: a fundamental change in asthma management: Treatment of asthma with short-acting bronchodilators alone is no longer recommended for adults and adolescents.Eur Respir J. 2019 Jun 27;53(6):1901046. doi: 10.1183/13993003.01046-2019. Print 2019 Jun. Eur Respir J. 2019. PMID: 31249014 No abstract available.
Dataset use reported in
-
Response: The most fundamental change in asthma management in 30 years?Eur Respir J. 2019 Nov 21;54(5):1901860. doi: 10.1183/13993003.01860-2019. Print 2019 Nov. Eur Respir J. 2019. PMID: 31754074 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical